Use of cytokeratin 8 immunohistochemistry for assessing cell death after radiofrequency ablation of breast cancers.
The effects of minimally invasive therapies such as radiofrequency ablation (RFA) and laser induced thermal therapy on breast carcinoma lesions usually is assessed by NADH diaphorase enzyme histochemistry for cell viability. NADH staining requires frozen material, however, with its associated poor morphology. We aimed to validate cytokeratin 8 (CK 8) immunohistochemistry as an alternative that works on paraffin sections. RFA was performed ex vivo on 20 breast resections after surgery and in vivo in eight patients who underwent general anesthesia followed by immediate resection. After treatment, specimens were lamellated and the tumors were divided into two equal parts. One part was fixed in neutral buffered formaldehyde for routine histopathological evaluation using hematoxylin and eosin (H & E) staining and CK 8 immunostaining. The other section was snap frozen and stored at -80° C for staining with NADH diaphorase. Both NADH diaphorase and CK 8 immunostaining demonstrated a clear and comparable demarcation between viable and nonviable tissues. The morphology of the CK 8 immunostained slides was much better, and fatty tissues could be judged readily by contrast to the NADH stained frozen sections, which had poor morphology and whose fatty parts were difficult to interpret. CK 8 immunohistochemistry seems to be well suited for assessing cell viability in breast tissue and for assessing the effects of RFA for breast cancer treatment. Because it can be applied to paraffin fixed material, it provides much better morphology than NADH staining and also can be applied to fatty tissues that usually are difficult to work up for frozen sections. Therefore, CK 8 immunohistochemistry may be preferred over NADH diaphorase staining for daily pathology practice for assessing the viability of breast carcinoma cells after RFA treatment.
Kreb
D L
DL
Department of Surgery, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands. dieuwertje_kreb@hotmail.com
Bosscha
K
K
Ernst
M F
MF
Rutten
M J C M
MJ
Jager
G J
GJ
van Diest
P J
PJ
van der Linden
J C
JC
D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry* / Q000201:enzymology / Q000473:pathology / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000201:enzymology / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods; D016923:Cell Death; D008058:Dihydrolipoamide Dehydrogenase / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053533:Keratin-8 / Q000032:analysis*; D008875:Middle Aged; D013194:Staining and Labeling; D016896:Treatment Outcome
D053533:Keratin-8; D008058:Dihydrolipoamide Dehydrogenase